A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

In the logistic regression model of the top 20 factors, significant associations for semaglutide initiation included being female (adjusted odds ratio, 2.30), using certain medication classes ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...